NIMHD Randomized Controlled Trial

The National Institutes of Health intends to award a sole-source contract to Kaiser Foundation Research Institute for a randomized controlled trial of a clinical decision-support tool that provides individualized exercise recommendations for breast cancer survivors, with capability statements due November 25, 2026, at 2:00 p.m. Eastern Time. The Set Aside line reads "No Set-Aside Used," and the sole-source intent comes from the attached Notice of Intent (75N94027R00004). The agency field lists the National Institute of Child Health and Human Development, while the title and attachment reference the National Institute on Minority Health and Health Disparities.

Work is performed within the Kaiser Permanente Northern California clinical setting. The contractor handles participant recruitment, study coordination, intervention implementation, data collection, and research deliverables, while the Government provides the existing tool, study protocol, and initial research instruments. The sole-source justification states that the initial evaluation must occur in the KPNC environment where the model was developed, given scientific uncertainty about applicability to other healthcare populations, and that the work requires access to KPNC's patients, clinicians, electronic health records, and clinical workflows.

Phase 1 covers feasibility and acceptability testing with approximately 10 clinicians and 30 breast cancer survivors. Phase 2 is a randomized controlled trial with approximately 64 clinicians and 624 breast cancer survivors divided into intervention and usual-care groups. The contract consists of a 12-month base period and two 12-month options, for a total potential period of performance of 36 months, with an anticipated award date of August 2027. The procurement is classified under NAICS 541715 and PSC AN12.